Oncopeptides AB (publ) (STO:ONCO)
Sweden flag Sweden · Delayed Price · Currency is SEK
5.76
-0.39 (-6.34%)
Aug 1, 2025, 5:29 PM CET

Oncopeptides AB Company Description

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally.

Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients.

The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells.

It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma.

The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells.

Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Oncopeptides AB (publ)
Oncopeptides AB logo
CountrySweden
Founded2000
IndustryBiotechnology
SectorHealthcare
Employees80
CEOSofia Heigis

Contact Details

Address:
Luntmakargatan 46
Stockholm, 111 37
Sweden
Phone46 86 15 20 40
Websiteoncopeptides.com

Stock Details

Ticker SymbolONCO
ExchangeNasdaq Stockholm
Fiscal YearJanuary - December
Reporting CurrencySEK
ISIN NumberSE0009414576
SIC Code2836

Key Executives

NamePosition
Sofia Heigis M.Sc.Chief Executive Officer
Prof. Rolf Larsson M.D., Ph.D.Founder
Prof. Rolf Lewensohn M.D., Ph.D.Founder
Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D.Founder
Dr. Kristina Luthman Ph.D.Founder
Prof. Hans Ehrsson M.D.Founder
Peter NygrenFounder
Henrik BergentoftChief Financial Officer
Eva Nordström M.Sc., MSc PharmChief Operating Officer and Deputy MD
Dr. Jakob Lindberg Med. LicChief Scientific Officer